368 related articles for article (PubMed ID: 26223461)
1. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
2. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
4. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
Pham A; Chen R
Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
[TBL] [Abstract][Full Text] [Related]
6. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.
van den Berg A; Visser L; Poppema S
Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793
[TBL] [Abstract][Full Text] [Related]
7. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML
Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027
[TBL] [Abstract][Full Text] [Related]
8. Rare expression of T-cell markers in classical Hodgkin's lymphoma.
Tzankov A; Bourgau C; Kaiser A; Zimpfer A; Maurer R; Pileri SA; Went P; Dirnhofer S
Mod Pathol; 2005 Dec; 18(12):1542-9. PubMed ID: 16056244
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab in classical Hodgkin's lymphoma.
Maly J; Alinari L
Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
[TBL] [Abstract][Full Text] [Related]
10. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F; Diefenbach CS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma.
Tzankov A; Zimpfer A; Went P; Maurer R; Pileri SA; Geley S; Dirnhofer S
Mod Pathol; 2005 Jan; 18(1):90-6. PubMed ID: 15389259
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in relapsed classical hodgkin lymphoma.
Dinner S; Advani R
J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
[TBL] [Abstract][Full Text] [Related]
14. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
[TBL] [Abstract][Full Text] [Related]
16. Aberrant FHIT protein expression in classical Hodgkin's lymphoma: a potential marker.
Zhao P; Lam AK; Lu YL; Zhong M; Chen LH; Pu XL
Pathology; 2006 Oct; 38(5):399-402. PubMed ID: 17008276
[TBL] [Abstract][Full Text] [Related]
17. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
Dasanu CA
J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
[TBL] [Abstract][Full Text] [Related]
18. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of K-1 (CD-30) marker in Hodgkin's disease.
Shakoor KA; Saleh A; Khanzada MS
J Pak Med Assoc; 2002 Oct; 52(10):442-7. PubMed ID: 12553671
[TBL] [Abstract][Full Text] [Related]
20. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
